Objective-We tested the hypothesis that endothelial peroxisome proliferator-activated receptor-γ protects against vascular thrombosis using a transgenic mouse model expressing a peroxisome proliferator-activated receptor-γ mutant (E-V290M) selectively in endothelium. Approach and Results-The time to occlusive thrombosis of the carotid artery was significantly shortened in E-V290M mice compared with nontransgenic littermates after either chemical injury with ferric chloride (5.1±0.2 versus 10.1±3.3 minutes; P=0.01) or photochemical injury with rose bengal (48±9 versus 74±9 minutes; P=0.04). Gene set enrichment analysis demonstrated the upregulation of NF-κB target genes, including P-selectin, in aortic endothelial cells from E-V290M mice (P<0.001). Plasma P-selectin and carotid artery P-selectin mRNA were elevated in E-V290M mice (P<0.05). P-selectin-dependent leukocyte rolling on mesenteric venules was increased in E-V290M mice compared with nontransgenic mice (53±8 versus 25±7 per minute; P=0.02). The shortened time to arterial occlusion in E-V290M mice was reversed by administration of P-selectin-blocking antibodies or neutrophil-depleting antibodies (P=0.04 and P=0.02, respectively) before photochemical injury. Conclusions-Endothelial peroxisome proliferator-activated receptor-γ protects against thrombosis through a mechanism that involves downregulation of P-selectin expression and diminished P-selectin-mediated leukocyte-endothelial interactions. (Arterioscler Thromb Vasc Biol. 2015;35:838-844. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
P eroxisome proliferator-activated receptor-γ (PPAR-γ) is a ligand-activated transcription factor that regulates lipid metabolism, adipocyte differentiation, blood pressure, and insulin sensitivity. 1 PPAR-γ is widely expressed in adipose tissue, liver, muscle, heart, macrophages, and bone, as well as in vascular endothelial and smooth muscle cells. 2 In patients with type 2 diabetes mellitus, treatment with therapeutic PPAR-γ agonists, such as thiazolidinediones, improves glucose control and lowers blood pressure 3 and also may protect from progression of atherosclerosis. [4] [5] [6] The observation that thiazolidinediones exert protective metabolic and vascular effects is consistent with genetic evidence indicating that subjects who carry dominant-negative PPAR-γ mutations develop severe insulin resistance and hypertension. 7 Vascular thrombosis is a major complication of cardiovascular disease and is strongly associated with risk factors, such as diabetes mellitus, metabolic syndrome, atherosclerosis, and hypertension, that are known to be modulated by PPAR-γ. 8 However, the influence of PPAR-γ on thrombotic susceptibility is not well understood. Some studies performed with cultured endothelial cells have suggested that PPAR-γ activation may protect against thrombosis by repressing the activation of the transcription factor NF-κB, downregulating the expression of proinflammatory cell adhesion molecules, and enhancing endothelial nitric oxide production. [9] [10] [11] [12] [13] In contrast, PPAR-γ agonists have been found to stimulate increased generation of procoagulant microparticles from monocytes and macrophages, 14 an observation that might help explain the paradoxical increase in risk of myocardial infarction seen in diabetic patients treated with some thiazolidinediones. 15 Thus, PPAR-γ agonists may exert opposing effects on thrombotic susceptibility via actions on different target cells. Clearly, a better understanding of the tissue-specific effects of PPAR-γ in regulating antithrombotic capacity is needed. 16 We previously developed transgenic mouse models in which dominant-negative mutations in the ligand-binding domain of human PPAR-γ (V290M or P467L) are selectively expressed in endothelium under the control of the vascular endothelial cadherin promoter. 17, 18 These mutations interfere with basal and agonist-induced PPAR-γ transcriptional activity and repress PPAR-γ target genes. 19, 20 We demonstrated that endothelium-specific V290M PPAR-γ (transgenic mouse model expressing the V290M PPAR-γ mutant selectively in endothelium [E-V290M]) transgenic mice exhibit increased susceptibility to endothelial vasomotor dysfunction when fed a high-fat diet 17 or crossed to apolipoprotein E-deficient mice. 21 In this study, we used the E-V290M murine model to test the hypothesis that endothelial PPAR-γ protects against arterial thrombosis in vivo and examine the mechanistic role of the endothelial cell adhesion molecule P-selectin.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Carotid Artery Thrombosis Is Accelerated in E-V290M Transgenic Mice
To investigate the potential antithrombotic functions of PPAR-γ specifically in endothelium, we studied transgenic mice expressing a dominant-negative human PPAR-γ mutant (V290M) targeted to vascular endothelium. Experimental thrombosis of the carotid artery was induced in male E-V290M and nontransgenic (non-Tg) mice by either transmural chemical injury with ferric chloride ( Figure 1A ) or luminal injury with the photoactivatable dye, rose bengal ( Figure 1B ). Compared with non-Tg mice, E-V290M mice exhibited a prothrombotic phenotype with both methods of carotid artery injury. After ferric chloride injury, the time to stable occlusion of the carotid artery was significantly shorter in E-V290M mice than non-Tg mice (P=0.01; Figure 1A) . The time to stable occlusion also was shorter in E-V290M mice compared with non-Tg mice after photochemical injury (P=0.04; Figure 1B ). Immunohistochemical staining demonstrated the presence of cells expressing the neutrophil antigen Ly-6 and tissue factor within the thrombosed lumen of the carotid artery after photochemical injury ( Figure 2 ). The Ly-6 and tissue factor-positive cells were localized near the intimal layer of the vessel wall, which suggested that activated neutrophils were interacting with the damaged endothelium or subendothelium at the site of injury. 
Venous Thrombosis Is Not Enhanced in E-V290M Mice
Dominant-Negative PPAR-γ Upregulates Endothelial NF-κB Target Genes, Including P-Selectin
To determine whether genes known to be important in the regulation of vascular thrombosis are altered by endothelial PPAR-γ interference, we analyzed an existing mRNA microarray data set (available from National Center for Biotechnology Information Gene Expression Omnibus at accession GSE11870) generated from gene expression profiling of endothelial cells derived from E-V290M mice and their non-Tg littermates. 17 We first queried the data set for genes with established roles in vascular thrombosis (Table) . Several of these genes exhibited a significant change in expression in endothelial cells of E-V290M mice, with the largest increase observed in the Selp gene encoding P-selectin (6.9-fold upregulation; P<0.01). The highly significant upregulation of Selp, a known NF-κB target gene, 22 suggested the possibility that the NF-κB pathway was activated in the endothelium of E-V290M mice. To further address this possibility, we queried the data set using a list of experimentally validated NF-κB target genes (http://bioinfo.lifl.fr/NF-KB/). In addition to statistically significant and robust increases in several individual NF-κB target genes ( Table I in group, displayed a significant increase in expression by gene set enrichment analysis (P<0.001; normalized enrichment score, 2.14).
E-V90M Mice Have Elevated the Levels of P-Selectin mRNA and Protein
To confirm that the altered expression of the Selp gene observed in the microarray data set analysis was associated with increased expression of P-selectin in E-V90M mice, we measured the levels of P-selectin mRNA in the carotid artery by quantitative real-time polymerase chain reaction. We found that P-selectin mRNA was elevated 2.3 fold in E-V290M mice compared with non-Tg mice (P=0.03; Figure 3A ).
Similarly, E-V290M mice had significantly elevated levels of circulating soluble P-selectin antigen in plasma compared with non-Tg mice (P=0.004; Figure 3B ). Because plasma soluble P-selectin can originate from platelets, as well as endothelial cells, 23 we also measured platelet P-selectin surface expression by flow cytometry. No differences in platelet surface P-selectin were observed between E-V290M and non-Tg mice at baseline or after activation of platelet alpha granule release with thrombin ( Figure 4A ). In addition, there Carotid artery thrombosis was induced by photochemical injury with rose bengal in male nontransgenic (non-Tg) and E-V290M mice, and the carotid arteries were harvested and subjected to immunohistochemical staining for neutrophils (Ly-6) or tissue factor (PAA524Mu01). Cells staining positively for neutrophils (thick arrows) and tissue factor (thin arrows) were detected within the thrombus adjacent to the intima. Scale bar=20 μm. were no differences in the level of fibrinogen binding at baseline or after activation with thrombin between E-V290M and non-Tg mice ( Figure 4B ). These findings suggest that the elevation of plasma soluble P-selectin in E-V290M mice was because of increased expression of P-selectin in endothelial cells rather than the release of P-selectin from platelets. These observations also demonstrate that the endotheliumtargeted dominant-negative V290M transgene does not have any appreciable effect on platelet activation in E-V290M mice.
E-V290M Mice Have Increased P-Selectin-Mediated Leukocyte-Endothelial Interactions
To assess the functional activity of endothelial P-selectin, we visualized leukocyte rolling on unstimulated mesenteric veins in real time using phase contrast video microscopy. We observed a 2-fold increase in rolling leukocytes per minute in E-V290M mice (53±8) compared with non-Tg mice (25±7; P=0.02; Figure 5 and Movies I and II in the online-only Data Supplement). Leukocyte rolling was almost completely inhibited by pretreatment with a P-selectin-blocking antibody in both E-V290M and non-Tg mice ( Figure 5 and Movie III in the online-only Data Supplement), demonstrating that leukocyte rolling was dependent on P-selectin.
Accelerated Carotid Artery Thrombosis in E-V290M Mice Is Dependent on P-Selectin and Neutrophils
To determine the mechanistic role of P-selectin-mediated endothelial-leukocyte interactions in the prothrombotic phenotype of E-V290M mice, mice were pretreated with either the P-selectin-blocking antibody or a neutrophil-depleting antibody (anti-Ly-6G) before inducing carotid artery thrombosis by photochemical injury. Treatment with anti-Ly-6G resulted in a 95% decrease in peripheral blood neutrophil count, from 1.39±0.65 to 0.07±0.04 K/μL (P=0.04). Compared with E-V290M mice pretreated with a control IgG, E-V290M mice pretreated with either the P-selectin-blocking antibody or the neutrophil-depleting antibody exhibited prolonged times to thrombotic occlusion (P=0.04 and P=0.02, respectively; Figure 6 ). Antibody pretreatment did not have any significant effects on the time to occlusion in non-Tg mice ( Figure 6 ). These findings suggest that the accelerated carotid artery thrombosis in E-V290M mice is dependent on both P-selectin and neutrophils.
Human PPAR-γ Transgene Expression in Blood Cells
We have shown previously that the vascular endothelial cadherin promoter confers endothelial-selective expression of dominant-negative human PPAR-γ in E-V290M mice. 18 Because vascular endothelial cadherin is also expressed in hematopoietic stem cells, 24 we measured the expression of human PPAR-γ V290M mRNA by quantitative real-time polymerase chain reaction in platelets and leukocytes, as well as in the lung, which are rich in endothelium ( Figure II online-only Data Supplement). As expected, strong expression of human PPAR-γ V290M mRNA was found in the lung. Trace expression of human PPAR-γ V290M mRNA also was detected in peripheral blood leukocytes, at a level that was >15 fold lower than that in the lung. No expression of human PPAR-γ V290M mRNA was detected in platelets.
Discussion
PPAR-γ is well known to have anti-inflammatory properties mediated by altered expression of proinflammatory and antiinflammatory genes. 1, 16, 21 However, despite an established association between inflammatory conditions and thrombotic risk, 25 the potential role of PPAR-γ in protecting from thrombosis remains poorly defined. Administration of high-affinity PPAR-γ agonists has been reported to protect against thrombosis in a mouse model of insulin resistance 26 and to have antiplatelet effects in vitro. 27, 28 In contrast, some PPAR-γ agonists have been reported to stimulate increased generation of procoagulant microparticles from monocytes and macrophages. 14 Moreover, the cell-specific influences of PPAR-γ in vascular endothelium on thrombotic susceptibility remain poorly defined. With this uncertainty in mind and in consideration of the growing public health burden of thrombotic complications associated with obesity and insulin resistance, 29 we used the E-V290M transgenic mouse model to delineate the effects on thrombosis of endogenous PPAR-γ expressed in endothelium.
The major findings from our study are that (1) cell-specific interference with endogenous PPAR-γ in vascular endothelium increases susceptibility to arterial thrombosis in mice and (2) the mechanism of accelerated thrombosis in E-V290M mice is mediated by upregulation of P-selectin and increased P-selectin-dependent endothelial-leukocyte interactions. We chose to use a dominant-negative approach rather than a PPAR-γ gene knockout approach for several reasons. First, dominant-negative mutations, such as V290M, while rare, are bonafide mutations that cause disease in human patients. 7 Second, the PPAR-γ null mouse has an embryonic lethal phenotype 30 and there are no null mutations known to exist in humans. Finally, the alternative approach of using an endothelial tissue-specific knockout model 31 has a major limitation. In the unliganded state, PPAR-γ binds to DNA and actively represses genes by recruiting a corepressor complex to the gene being silenced. 32 When a ligand is present, the corepressor complex is replaced by a coactivator complex, leading to gene activation. Deleting PPAR-γ has a similar effect as ligand activation because there is a small induction of gene expression because of the loss of active repression. This does not occur with the use of dominant-negative PPAR-γ mutants. As expected, we observed strong expression of the PPAR-γ V290M transgene in endothelium. We also detected trace expression of the transgene by quantitative real-time polymerase chain reaction in peripheral blood mononuclear cells ( Figure II in the online-only Data Supplement). It is possible that the low-level expression of the transgene in peripheral blood cells may be because of residual activity of the vascular endothelial cadherin promoter in cells of myeloid lineage. 24 Alternatively, it may represent the presence of trace amounts of circulating endothelial cells in the mononuclear cell fraction.
PPAR-γ has been reported to inhibit the activation of NF-κB in endothelial cells, 16 and our gene expression analysis confirmed that known NF-κB target genes are significantly upregulated in aortic endothelial cells of E-V290M mice. In particular, we identified P-selectin as an NF-κB target gene that is highly upregulated in the endothelium of E-V290M mice compared with non-Tg mice. P-selectin (CD62P) is an inducible cell surface leukocyte adhesion molecule that mediates initial interactions between circulating neutrophils and the activated endothelium. 23 In accordance with the upregulation of P-selectin seen in the microarray data set analysis, we observed increased levels of P-selectin mRNA in the carotid artery and increased circulating soluble P-selectin in the plasma of E-V290M mice (Figure 3 ). Importantly, the increased expression of endothelial P-selectin was accompanied by increased leukocyte rolling, indicating that the P-selectin expressed in E-V290M mice was functional in mediating increased leukocyte-endothelial interactions. In addition to mediating leukocyte recruitment to activated endothelium, P-selectin can promote thrombosis by facilitating platelet adhesion and inducing the generation of procoagulant microparticles and neutrophil extracellular traps. 23, 33 We therefore reasoned that P-selectin may be a key mediator of the prothrombotic phenotype of E-V290M mice.
The prothrombotic phenotype of E-V290M mice was apparent when carotid artery thrombosis was induced by either chemical injury with ferric chloride or photochemical injury with rose bengal (Figure 1 ). For subsequent mechanistic experiments, we chose to focus on the photochemical injury model because it is more endothelium dependent, 34 whereas the ferric chloride injury model is partially mediated by red blood cells. 35 To determine the role of P-selectin-mediated leukocyte-endothelial interactions in the enhanced thrombotic susceptibility of E-V290M mice, we pretreated mice with a P-selectin-blocking antibody that was shown to almost completely eliminate leukocyte rolling ( Figure 5 ). We found that the P-selectin-blocking antibody largely reversed the prothrombotic effect of endothelium-specific PPAR-γ interference ( Figure 6 ). We also observed a similar protective antithrombotic effect after depletion of >95% of the circulating neutrophils in E-V290M mice ( Figure 6 ). Together, these findings suggest that endogenous endothelial PPAR-γ protects from thrombosis through a mechanism that involves downregulation of P-selectin expression, perhaps by antagonizing the transcriptional effects of NF-κB and diminished P-selectinmediated leukocyte-endothelial interactions. Both ferric chloride and rose bengal induce vascular injury via oxidative mechanisms, leading to endothelial damage and denudation. 34 The thrombotic response to oxidative injury is thought to be initiated by the adhesion of platelets and leukocytes to the exposed subendothelium. However, recent findings suggest that, at least for the ferric chloride model, the injured endothelium may be retained after ferric chloride exposure and may contribute to thrombosis. 35, 36 Our findings suggest that expression of P-selectin on the retained injured endothelium contributes to leukocyte adhesion and thrombosis after oxidative injury. We acknowledge that it is possible that additional endothelial PPAR-γ or NF-κB target genes, such as E-selectin, VCAM-1, ICAM-1, and tissue factor, also may contribute to the prothrombotic phenotype of E-V290M mice. However, none of these genes emerged from the gene expression data set analysis as significantly upregulated in endothelial cells from E-V290M mice. We note that genes encoding protease-activated receptor-2 (F2rl1) and plasminogen activator inhibitor-1 (Serpine1) were upregulated 5 fold and 4 fold, respectively, with a borderline level of statistical significance (P<0.1; Table) . These may be attractive target genes for future study.
The lack of a venous thrombosis phenotype in E-V290M mice using the inferior vena cava stasis model is surprising because P-selectin is thought to play a mechanistic role in venous thrombosis. 37 We consider these findings to be interesting, however, because they suggest that nonendothelial sources of P-selectin (eg, platelet P-selectin) may play a greater role than endothelial P-selectin in driving venous thrombosis. In contrast, endothelial P-selectin may contribute more directly to arterial thrombosis. In support of this idea, it has been suggested that multiple pools of P-selectin promote venous thrombogenesis. 38 Our findings may have implications for the clinical observation that, despite their generally protective metabolic and cardiovascular effects in diabetic patients, some thiazolidinediones have been found to paradoxically increase the risk of thrombotic vascular complications, such as myocardial infarction. 15 Our results suggest that activation of PPAR-γ specifically in vascular endothelium is antithrombotic and protective, raising the possibility that the apparent prothrombotic effects of systemically administered PPAR-γ agonist may be mediated through effects in other cell types. The protective antithrombotic effect of the P-selectin-blocking antibody observed in E-V290M mice suggests that antagonism of P-selectin may be potential therapeutic approach to prevent thrombosis in patients with impaired PPAR-γ function because of obesity or insulin resistance. Oral P-selectin-blocking agents are being developed for several different clinical indications. [39] [40] [41] [42] In summary, this study demonstrates that selective inactivation of PPAR-γ in vascular endothelium results in a prothrombotic phenotype characterized by upregulation of P-selectin and other NF-κB target genes. Our data further demonstrate that interference with endothelial PPAR-γ leads to accelerated thrombosis through a mechanism in which increased expression of P-selectin causes enhanced leukocyte recruitment to the vessel wall. These findings suggest that one mechanism for protection against thrombosis by endogenous endothelial PPAR-γ is by suppressing P-selectin-mediated leukocyteendothelial interactions.
